NEW YORK (GenomeWeb) – The University Hospital Southampton NHS Foundation Trust (UHS) and NantHealth have formed a three-year partnership that will provide sequencing and analytics services for oncology.
The partners will use advanced molecular, genomic, and proteomic techniques, treatment decision support, and informatics capabilities to inform personalized medicine and coordinate care for cancer patients.
Under the terms of the agreement, the UHS will use NantHealth's UK-based supercomputing infrastructure and its NantTransporter system to move raw sequence data from sequencing machines to analysis applications. The UHS will also have access to NantContraster, NantHealth's analytics platform for interpretation and annotation as well as clinical reporting tools. In addition, the UHS will have access to NantHealth's clinical operating system, which will be used to capture and record cancer clinical and outcomes data, making it possible to identify and match patients to suitable clinical trials.
The UHS believes the partnership will enable it to improve care and provide more personalized treatments for cancer patients. The partnership "will allow us to take an important next step in the use of molecular medicine for the benefit of our cancer patients across the Wessex region," UHS CEO Fiona Dalton said in a statement.
"We are proud to be amongst the first organizations … to deliver precision diagnostics alongside guided cancer decision support to deliver integrated care delivery solutions," she continued. "We believe this will facilitate an elevated standard of care for our patients and will enable UHS to be at the forefront of specialist cancer services and clinical science in the UK."
Financial and other terms of the agreement were not disclosed.